Horizon Pharma plc to Present at the Stifel 2014 Healthcare Conference
(firmenpresse) - DUBLIN, IRELAND -- (Marketwired) -- 11/11/14 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that Robert F. Carey, executive vice president and chief business officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:45 p.m. Eastern Time in New York, NY. Mr. Carey will provide an overview of the Company and its corporate activities.
The presentation will be webcast live and may be accessed by visiting Horizon''s website at . A replay of the webcast will be available for 10 business days.
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients'' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon''s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole). The Company expects to begin marketing PENNSAID® (diclofenac sodium topical solution) 2% w/w in the U.S. in January 2015. Horizon''s global headquarters are in Dublin, Ireland. For more information, please visit
Elizabeth M. Higashi, CFA
Vice President, Investor Relations
+1 224-383-3285
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.11.2014 - 15:05 Uhr
Sprache: Deutsch
News-ID 1317427
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
DUBLIN, IRELAND
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 145 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Horizon Pharma plc to Present at the Stifel 2014 Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Horizon Pharma plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
